Lol if that’s how they choose to use it, that’s fine by me. I really think next six to twelve months could be the making of this company with Boehringer results, bronchitol, and LOXL-2. BUT and this is a high ‘but’ I think it’s pretty ballsy to risk leaving finalization of the LOXL-2 product more or less until after the Boehringer results. If the Boehringer results are good, that’s one matter, but I think we’d be in a fairly poor negotiating position if the results are suboptimal. Still a 2 year runway in cash is reassuring. I agree however that this may be a pretty takeover target. Cash on had alone makes up 30% of the market cap.
PXS Price at posting:
23.0¢ Sentiment: Hold Disclosure: Held
